ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: PP08

Living Well Despite the Challenges of Sjögren’s Disease and Systemic Lupus Erythematous: My Perspective as a Health Care Provider and Patient

Matt Makara, Casey Hogan

Meeting: ACR Convergence 2025

Keywords: autoimmune diseases, immunology, Lupus nephritis, Renal, Sjögren's syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (PP01-PP08) Patient Perspectives Poster

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Typically, the diagnosis of any autoimmune condition can be challenging and take years. In my case, my diagnosis of Sjögren’s disesase (SjD) was established while hospitalized in cardiac intensive care due to renal failure and cardiomyopathy as a young patient. Over time and years later, my health landscape evolved to an additional diagnosis of systemic lupus erythematous (SLE) with kidney involvement, specifically lupus nephritis. My career as an optometrist allows me a unique perspective on not only understanding the clinical aspects and management of my conditions, but also gives me the knowledge and compassion to treat my patients and advocate for increased awareness of SjD and its multi-systemic nature within the healthcare community.

I was 23 years old and a 3rd year optometry student when I was first diagnosed. I initially presented to my local emergency room with mental confusion, significant tachycardia, nausea, and lethargy.  Clinical examination revealed metabolic acidosis secondary to type 1 distal renal tubular acidosis, hypokalemia, renal failure, and metabolic encephalopathy and cardiomyopathy. The diagnosis was SjD w/Type 1 renal tubular acidosis based on clinical laboratory studies. We were just learning about autoimmune disease in our courses, and I recall the immediate concern of being so young and so sick, and the uncertainty of the disease.

Intervention: Management of any systemic autoimmune disease requires a team approach and collaborative care and the number of subspecialties who are a part of my healthcare team has grown over the last thirty years. This is a key reason that I believe in staying educated on my disease by utilizing reliable resources such as PubMed to review current literature pertaining to my disease. This, in turn, helps ensure that I’m able to communicate with my health care team and that they’re kept up to date on best practices and considerations for my optimal care.

An important example of these collaborative efforts was educating my urologist on the complex nature of my simple lithotripsy procedure for nephrolithiasis and the risk for urinary tract infections that had led to sepsis and multiple hospitalizations for me in the past. This education and awareness was much appreciated by my healthcare team, who often times mistakenly think of SjD as “just dry eye disease”.

Maintenance: Continuing my own education and communicating and advocating for myself with my healthcare team to ensure we’re on the same page is an ongoing effort. My ocular complications have led to a lifelong journey of specializing in the management of ocular surface disease and my continued education and interest in this field facilitated becoming a Diplomat of the American Academy of Optometry in anterior segment disease, which has helped both myself as individual as well as the many patients I treat.

Quality of Life: While education and stronger communication have helped improve care and Quality of Life, there are still gaps in knowledge, management, and treatment options that influence how I’m able to live in a given period.

Takeaway: My efforts to stay educated on my disease and openly communicate with my healthcare team have helped strengthen these relationships and provided a degree of confidence in my own understanding of the disease and what I’m experiencing as well as those who I trust with caring for me. My perspective as an eye care specialist has helped me in my pursuit of quality of life, and ultimately my empathy and true understanding has helped countless patients and other healthcare providers understand this complex disease. 


Disclosures: M. Makara: Disclosure Not Received; C. Hogan: None

To cite this abstract in AMA style:

Makara M, Hogan, C. Living Well Despite the Challenges of Sjögren’s Disease and Systemic Lupus Erythematous: My Perspective as a Health Care Provider and Patient [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/living-well-despite-the-challenges-of-sjogrens-disease-and-systemic-lupus-erythematous-my-perspective-as-a-health-care-provider-and-patient/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/living-well-despite-the-challenges-of-sjogrens-disease-and-systemic-lupus-erythematous-my-perspective-as-a-health-care-provider-and-patient/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology